These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8845552)

  • 1. Comment: piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
    Wang F; Schwenk MH
    Ann Pharmacother; 1995 Oct; 29(10):1051-2. PubMed ID: 8845552
    [No Abstract]   [Full Text] [Related]  

  • 2. Piperacillin-Tazobactam: a new beta-lactam-beta-lactamase inhibitor combination.
    Daniel KP; Krop LC
    Pharmacotherapy; 1996; 16(2):149-62. PubMed ID: 8820460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.
    Occhipinti DJ; Pendland SL; Schoonover LL; Rypins EB; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2511-7. PubMed ID: 9371358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase.
    Leleu G; Kitzis MD; Vallois JM; Gutmann L; Decazes JM
    Antimicrob Agents Chemother; 1994 Feb; 38(2):195-9. PubMed ID: 8192442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical studies of tazobactam/piperacillin (TAZ/PIPC) in pediatric patients].
    Waga S; Yokoyama M; Tsushima T; Chiba C; Saito T; Okamoto T; Asuka T; Kitazawa J; Tateyama N; Sato Y; Takahashi Y
    Jpn J Antibiot; 1998 May; 51(5):305-18. PubMed ID: 9693964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetic and clinical evaluation of tazobactam/piperacillin in the pediatric field].
    Toyonaga Y; Ishihara T; Tezuka T; Nakamura H
    Jpn J Antibiot; 1998 May; 51(5):325-45. PubMed ID: 9693966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues.
    Incavo SJ; Ronchetti PJ; Choi JH; Wu H; Kinzig M; Sörgel F
    Antimicrob Agents Chemother; 1994 Apr; 38(4):905-7. PubMed ID: 8031071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections.
    Sörgel F; Kinzig M
    Eur J Surg Suppl; 1994; (573):39-44. PubMed ID: 7524794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-lactam/beta-lactamase inhibitor combinations: pharmacodynamic considerations and possible role in the management of bacterial infections in the neutropenic host.
    Okereke C; Dudley MN
    J Antimicrob Chemother; 1998 Jun; 41 Suppl D():43-9. PubMed ID: 9688450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
    Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of piperacillin/tazobactam treatment on human bowel microflora.
    Nord CE; Brismar B; Kasholm-Tengve B; Tunevall G
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():61-5. PubMed ID: 8383656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
    Schoonover LL; Occhipinti DJ; Rodvold KA; Danziger LH
    Ann Pharmacother; 1995 May; 29(5):501-14. PubMed ID: 7655135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection.
    Bourget P; Lesne-Hulin A; Le Reveillé R; Le Bever H; Carsin H
    Antimicrob Agents Chemother; 1996 Jan; 40(1):139-45. PubMed ID: 8787895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breakpoint determination: piperacillin/tazobactam.
    Eur J Clin Microbiol Infect Dis; 1993 Jul; 12(7):575-7. PubMed ID: 8404929
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H.
    Mattoes HM; Capitano B; Kim MK; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
    Chemotherapy; 2002 May; 48(2):59-63. PubMed ID: 12011536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulation and steady-state pharmacokinetic data from hospitalized patients.
    Rotschafer JC; Ullman M
    Ann Pharmacother; 2009 Nov; 43(11):1887-9. PubMed ID: 19809005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis.
    Mueller SC; Majcher-Peszynska J; Hickstein H; Francke A; Pertschy A; Schulz M; Mundkowski R; Drewelow B
    Antimicrob Agents Chemother; 2002 May; 46(5):1557-60. PubMed ID: 11959598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic characteristics of piperacillin/tazobactam.
    Sörgel F; Kinzig M
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S14-20. PubMed ID: 7962984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam.
    Sörgel F; Kinzig M
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():39-60. PubMed ID: 8383655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of continuous infusion of piperacillin-tazobactam in children with fever and neutropenia.
    Delvallée M; Mazingue F; Abouchahla W; Delebarre M; Wallet F; Courcol R; Kipnis E; Dessein R
    Pediatr Infect Dis J; 2013 Sep; 32(9):962-4. PubMed ID: 23629023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.